Effects of cotrimoxazole prophylactic treatment on adverse health outcomes among HIV-exposed, uninfected infants

Pediatric Infectious Disease Journal

Volumn 31, Issue 8, 2012, Pages 842-847

  Dow, Anna ^a   Kayira, Dumbani ^b   Hudgens, Michael ^a   Van Rie, Annelies ^a   King, Caroline C ^c   Ellington, Sascha ^c   Kourtis, Athena ^c   Turner, Abigail Norris ^d   Meshnick, Steven ^a   Kacheche, Zebrone ^b   Jamieson, Denise J ^c   Chasela, Charles ^b   Van Der Horst, Charles ^e  

^a The University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

cotrimoxazole; HIV; infants; malaria

Indexed keywords

COTRIMOXAZOLE;

ADVERSE OUTCOME; ANEMIA; ARTICLE; CHILD; CONTROLLED STUDY; DEATH; DIARRHEA; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALARIA; MENINGITIS; OUTCOME ASSESSMENT; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; VOMITING;

ANEMIA; ANTI-RETROVIRAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTIMALARIALS; BODY WEIGHT; BREAST FEEDING; CHI-SQUARE DISTRIBUTION; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; MALARIA; MOTHERS; STATISTICS, NONPARAMETRIC; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84863980508     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31825c124a     Document Type: Article

References (36)

1. UNAIDS. AIDS epidemic update. 2009. Available at: http://data.unaids. org/pub/Report/2009/JC1700-Epi-Update-2009-en.pdf. Accessed May 1, 2011.
2. Cotton MF, Schaaf HS, Lottering G, et al.; PACTG 1041 Team. Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting. Int J Tuberc Lung Dis. 2008;12:225-227.
3. Mermin J, Lule J, Ekwaru JP, et al. Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members. AIDS. 2005;19:1035-1042.
4. Mofenson LM, Oleske J, Serchuck L, et al. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. Clin Infect Dis. 2005;40(suppl 1):S1-S84.
5. World Health Organization. World Malaria Report. Geneva: WHO; 2009.
6. Okiro EA, Al-Taiar A, Reyburn H, et al. Age patterns of severe paediatric malaria and their relationship to Plasmodium falciparum transmission intensity. Malar J. 2009;8:4.
7. World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults in resource-limited settings. Geneva: WHO; 2006.
8. Anglaret X, Chêne G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet. 1999;353:1463-1468.
9. Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet. 2004;364:1428-1434.
10. Campbell J, Moore D, Degerman R, et al. HIV-infected Ugandans on HAART with CD4 Counts >200 Cells/mm3 who discontinue cotrimoxazole have increased risk of malaria and diarrhea. CROI; 2009; Montreal Canada,.
11. Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet. 1999;353:1469-1475.
12. Thera MA, Sehdev PS, Coulibaly D, et al. Impact of trimethoprim- sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis. 2005;192:1823-1829.
13. Zar HJ, Dechaboon A, Hanslo D, et al. Pneumocystis carinii pneumonia in South African children infected with human immunodeficiency virus.Pediatr Infect Dis J. 2000;19:603-607.
14. Mermin J, Ekwaru JP, Liechty CA, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet. 2006;367:1256-1261.
15. Kamya MR, Gasasira AF, Achan J, et al. Effects of trimethoprim- sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS. 2007;21:2059-2066.
16. Coutsoudis A, Pillay K, Spooner E, et al. Routinely available cotrimoxazole prophylaxis and occurrence of respiratory and diarrhoeal morbidity in infants born to HIV-infected mothers in South Africa. S Afr Med J. 2005;95:339-345.
17. Gill CJ, Mwanakasale V, Fox MP, et al. Effect of presumptive co-trimoxazole prophylaxis on pneumococcal colonization rates, seroepidemiology and antibiotic resistance in Zambian infants: a longitudinal cohort study. Bull World Health Organ. 2008;86:929-938.
18. World Health Organization. World Malaria Report 2008. Geneva: WHO; 2008.
19. van der Horst C, Chasela C, Ahmed Y, et al.; Breastfeeding, Antiretroviral, and Nutrition Study Team. Modifications of a large HIV prevention clinical trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi. Contemp Clin Trials. 2009;30:24-33.
20. Chasela CS, Hudgens MG, Jamieson DJ, et al.; BAN Study Group. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010;362:2271-2281.
21. Allison PD. Survival Analysis Using SAS. Cary, NC: SAS Institute, Inc.; 1995.
22. Rothman KJ, Greenland S. Modern Epidemiology. Philadelphia, PA: Lippincott-Raven; 1998.
23. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol. 1993;138:923-936.
24. World Health Organization. Child Growth Standards. WHO Anthro (version 3.2.2, January 2011) and macros. 2011. Available at: http://www.who.int/ childgrowth/software/en/. Accessed December 17, 2011.
25. Sandison TG, Homsy J, Arinaitwe E, et al. Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. BMJ. 2011;342:d1617.
26. Snow RW, Nahlen B, Palmer A, et al. Risk of severe malaria among African infants: direct evidence of clinical protection during early infancy. J Infect Dis. 1998;177:819-822.
27. Reyburn H, Mbatia R, Drakeley C, et al. Association of transmission intensity and age with clinical manifestations and case fatality of severe Plasmodium falciparum malaria. JAMA. 2005;293:1461-1470.
28. de Moraes-Pinto MI, Almeida AC, Kenj G, et al. Placental transfer and maternally acquired neonatal IgG immunity in human immunodeficiency virus infection. J Infect Dis. 1996;173:1077-1084.
29. Farquhar C, Nduati R, Haigwood N, et al. High maternal HIV-1 viral load during pregnancy is associated with reduced placental transfer of measles IgG antibody. J Acquir Immune Defic Syndr. 2005;40:494-497.
30. Chougnet C, Kovacs A, Baker R, et al. Influence of human immunodeficiency virus-infected maternal environment on development of infant interleukin-12 production. J Infect Dis. 2000;181:1590-1597.
31. Clerici M, Saresella M, Colombo F, et al. T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. Blood. 2000;96:3866-3871.
32. Watera C, Todd J, Mutonyi G, et al. Effects of cotrimoxazole on hematologic parameters in HIV-infected adults in a community-based clinic in Entebbe, Uganda. J Acquir Immune Defic Syndr. 2007;46:369-371.
33. Aizire J, Fowler MG, Wang J, et al. Extended prophylaxis with nevirapine and cotrimoxazole among HIV-exposed uninfected infants is well tolerated. AIDS. 2012;26:325-333.
34. Chintu C, Bhat GJ, Walker AS, et al.; CHAP Trial Team. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet. 2004;364:1865-1871.
35. WHO Collaborative Study Team on the Role of Breastfeeding on Prevention of Infant Mortality. Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. Lancet 2000;355:1517-1524.
36. Coutsoudis A, Kindra G, Esterhuizen T. Impact of cotrimoxazole prophylaxis on the health of breast-fed, HIV-exposed, HIV-negative infants in a resource-limited setting. AIDS. 2011;25:1797-1799.